The breast cancer cell line
MCF-7 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). The cells were cultured in
RPMI 1640 medium (Gibco BRL, Carlsbad, CA, USA) supplemented with 10%
FBS (Capricorn, Ebsdorfergrund, Germany) and 1% penicillin-streptomycin. The ginsenoside Rg3 and Rh2 (LKT Labs, St. Paul, Minnesota, USA), Korean Red Ginseng (KRG) extract (kindly donated by Korea Ginseng Co., Daejon, Korea), and
5-Aza-2′-deoxycytidine (
5-Aza; Sigma-Aldrich, St. Louis, MO, USA) were used to treat the cells in a 60-mm culture dish at a confluence of 50-70%. The contents of various ginsenosides in KRG was determined as described previously [18] (
link). Rg3 and Rh2 stocks were prepared with 20 mM in 100% ethanol and used in final concentrations of 20 and 50 μM. KRG extract was dissolved in distilled water and treated to cells at final concentrations of ∼200 μg/ml.
5-Aza stock was prepared with 10 mM in 100%
DMSO (Sigma-Aldrich) and treated to cells in final concentrations of 2.5, 5, and 10 μM. Twenty-four hours after treatment by Rg3, Rh2, KRG extract, or
5-Aza, the cells were harvested, washed with PBS, and trypsinized using 0.05%
trypsin-EDTA (Gibco BRL).
Ham J., Jeong D., Park S., Kim H.W., Kim H, & Kim S.J. (2019). Ginsenoside Rg3 and Korean Red Ginseng extract epigenetically regulate the tumor-related long noncoding RNAs RFX3-AS1 and STXBP5-AS1. Journal of Ginseng Research, 43(4), 625-634.